|1.||Iwamoto, Jun: 27 articles (10/2015 - 10/2003)|
|2.||Sato, Yoshihiro: 18 articles (01/2013 - 03/2005)|
|3.||Boonen, Steven: 15 articles (01/2014 - 09/2004)|
|4.||Takeda, Tsuyoshi: 15 articles (09/2012 - 10/2003)|
|5.||Eastell, Richard: 11 articles (12/2014 - 04/2004)|
|6.||Watts, Nelson B: 9 articles (09/2011 - 01/2002)|
|7.||Reginster, Jean-Yves: 8 articles (06/2014 - 01/2003)|
|8.||Delmas, Pierre D: 8 articles (01/2013 - 11/2002)|
|9.||Matsumoto, Hideo: 8 articles (01/2013 - 05/2008)|
|10.||Miller, Paul D: 7 articles (01/2014 - 12/2005)|
01/01/2009 - "In an earlier interim report, we found that 1 year of risedronate therapy resulted in significant increases in bone mineral density (BMD) and a significant reduction in vertebral fractures compared to control in men with osteoporosis. "
01/01/2009 - "Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study."
06/01/2008 - "Monotherapy with alfacarcidol was effective for secondary osteoporosis in children, but when used in combination with risedronate it was even more effective in improving BMD. "
09/01/2014 - "Also in male and steroidal osteoporosis, clinical controlled studies have shown that risedronate is effective in decreasing vertebral fracture incidence. "
01/01/2006 - "At a hypothetical threshold value of euro 40,000 per QALY gained, the results in this study indicate that risedronate is a cost-effective treatment in elderly women at the threshold of osteoporosis (i.e., a T-score of -2.5) with prevalent vertebral fractures in Sweden, Finland, Belgium, and Spain."
07/01/2015 - "Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. "
01/01/2013 - "Risedronate is effective in the treatment of postmenopausal osteoporosis in oral daily, weekly, or on two consecutive days per month doses. "
01/01/2009 - "Risedronate, an orally administered pyridinal bisphosphonate, is effective in the treatment and prevention of postmenopausal osteoporosis. "
01/01/2008 - "Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. "
01/01/2003 - "Based on this analysis, risedronate is a cost-effective treatment for postmenopausal osteoporosis within the German health care system, offering benefits for osteoporotic patients and for budget decision-makers."
02/01/2012 - "We previously reported that risedronate improved the structural parameters of the proximal femur, as well as lumbar spine and proximal femoral bone mineral density (BMD), after 1 year of therapy by suppressing bone resorption in patients with an increased risk of fracture. "
01/01/2007 - "At the spine, however, this correlation exists down to a 40% fall in bone resorption markers; larger drops did not provide further protection against fractures in patients taking risedronate in one evaluation of this relationship. "
09/01/2014 - "Under the metabolic profile, these studies have also shown that risedronate activity can reduce bone resorption markers and increase bone density values at lumbar and femoral level. "
12/01/2001 - "In the clinical trials reviewed here, antiresorptive therapy using the bisphosphonate, risedronate, significantly reduced the incidence of vertebral and nonvertebral fractures, increased BMD in both early and late menopausal women, and decreased biochemical measures of bone resorption. "
01/01/2000 - "In this early phase II study, we analyzed the effects of short-term, high-dose treatment with risedronate, a potent pyridinyl bisphosphonate, on markers of bone resorption and formation. "
|4.||Hip Fractures (Intertrochanteric Fractures)
05/01/2008 - "The new risedronate 75mg monthly formulation, administered on two consecutive days, is therefore the first and only oral monthly therapy with proven efficacy in reducing the risk of vertebral, non-vertebral and hip fractures, and a safety profile confirmed by Phase III trials and 8-year post-marketing experience of risedronate. "
03/12/2007 - "Risedronate for the prevention of hip fractures: concern about validity of trials."
08/01/2002 - "Clinical studies conducted in Japan, North America and/or Europe revealed that risedronate reduces the risks of hip fractures and vertebral fractures by around 30% and around 50% compared with placebo over three years, respectively, and increases lumber spine BMD by around 5% at one year after starting treatment. "
02/01/2012 - "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients. "
12/01/2011 - "The RR for hip fractures in the risedronate group as compared with the placebo group was 0.20 (95% CI 0.06 to 0.66). "
03/01/2014 - "The mean pain score based on the visual analogue scale showed significant reduction in the risedronate group compared with the control group. "
02/12/2001 - "Risedronate decreases pagetic bone pain and induces radiological improvement in pagetic lesions. "
01/01/2013 - "The two largest studies were conducted with risedronate in the treatment of knee OA, for which meta-analyses were performed for pain and functional outcomes. "
12/01/2011 - "By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. "
07/01/2006 - "1. The antinociceptive effect of risedronate in experimental pain models in rats and mice was investigated in the present study. "
|1.||Alendronate (Alendronate Sodium)
|3.||Etidronic Acid (HEDP)
|5.||zoledronic acid (zoledronate)
|9.||ibandronic acid (Boniva)
|10.||risedronic acid (risedronate)
|2.||Drug Therapy (Chemotherapy)
|5.||Stem Cell Transplantation